Comparing surgery and imaging methods for staging cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of surgery staging versus image staging in patients with locally advanced cervical cancer. Eligible participants will be assigned to either the image staging group, receiving standard chemoradiation, or the surgery staging group, undergoing lymph node dissection followed by chemoradiation. The primary goal is to determine which method leads to better progression-free survival and overall survival rates. This multicenter, prospective trial will provide insights into optimal staging approaches for this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The patients with good compliance, voluntarily signed the informed consent form and participated in the study.
2. Histopathology: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
3. Stage (FIGO2018): IB3, IIA2, IIB-IVA;
4. ECOG score: 0 \~ 1;
5. The expected survival \>6 months;
6. The result of a pregnancy test (serum or urine) within seven days must be negative for women of childbearing age, who must take contraception during the trial.

Exclusion Criteria:

1. Activity or uncontrol severe infection;
2. Liver cirrhosis or other decompensated liver disease;
3. A history of immune deficiency, including HIV positive or a congenital immunodeficiency disease;
4. Chronic renal insufficiency or renal failure;
5. Other malignancies were diagnosed within five years or needed treatments;
6. Myocardial infarction, severe arrhythmia and congestive heart failure with grade ≥2 (New York heart association);
7. The CT/MRI/PET/CT show that the para-aortic lymph nodes are positive;
8. A history of pelvic artery embolization;
9. A history of pelvic radiotherapy;
10. A history of partial hysterectomy or radical hysterectomy;
11. A history of severe allergic reaction to platinum drugs;
12. The drugs for the treatment of concomitant disease seriously impaired liver or kidney function, such as tuberculosis;
13. Patients who cannot understand the research regimen and refuse to sign the informed consent form;
14. Other concomitant diseases or special conditions seriously endanger the patient's health or interfere with the trial.

Where it's running

• Chongqing University Cancer Hospital
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Principal investigator: Dongling Zou, M.D. — Chongqing University Cancer Hospital
• Study coordinator: Dongling Zou, M.D.
• Email: cqzl_zdl@163.com
• Phone: 13657690699

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iparomlimab/Tuvonralimab with nab-paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer

  This trial tests whether adding Iparomlimab/Tuvonralimab to nab-paclitaxel and cisplatin before surgery can shrink locally advanced cervical cancer and safely be given to adult women.

  Recruiting Phase 2 Xijing Hospital · Xi'an, Shaanxi · NCT07876154

• Vitamin D Status and Outcomes in Locally Advanced Cervical Cancer treated with chemoradiotherapy

  This study tests whether pretreatment vitamin D levels can predict how well women with locally advanced cervical cancer respond to standard chemoradiotherapy.

  Recruiting University of Kragujevac · Kragujevac, Šumadija · NCT07743918

• Patient-tailored 3D-printed ARCHITECT applicator for cervical cancer brachytherapy

  We’re testing a 3D-printed, one-time use ARCHITECT applicator to see if it safely helps deliver brachytherapy for locally advanced cervical cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07435987

• Nanocrystalline megestrol acetate with chemoradiation for locally advanced cervical cancer

  This Phase 1 trial tests whether taking nanocrystalline megestrol acetate by mouth can prevent or reduce weight and muscle loss in adults with locally advanced cervical cancer who are receiving concurrent chemoradiotherapy.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07338487

• Cadonilimab plus cisplatin given before surgery for locally advanced cervical cancer

  This study will test whether giving cadonilimab together with cisplatin before surgery helps people with resectable, locally advanced cervical cancer.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07104149

• Pre-surgery iparomlimab and tuvonralimab with chemotherapy for locally advanced cervical cancer

  This phase 2 trial tests whether giving iparomlimab and tuvonralimab with chemotherapy before surgery helps people with locally advanced cervical cancer shrink their tumors and improve outcomes.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07055399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.